Q4 2014 13F Holders as of 12/31/2014
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
123M
-
Number of holders
-
130
-
Total shares
-
91.2M
-
Shares change
-
+2.07M
-
Total reported value, excl. options
-
$880M
-
Value change
-
+$20.2M
-
Put/Call ratio
-
1.66
-
Number of buys
-
63
-
Number of sells
-
-46
-
Price
-
$9.65
Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q4 2014
140 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q4 2014.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 130 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 91.2M shares
of 123M outstanding shares and own 73.97% of the company stock.
Largest 10 shareholders include Third Security, LLC (19.8M shares), IRIDIAN ASSET MANAGEMENT LLC/CT (7.27M shares), BB Biotech AG (6.83M shares), VANGUARD GROUP INC (6.28M shares), BlackRock Fund Advisors (4.1M shares), First Eagle Investment Management, LLC (3.99M shares), State Street Corp (3.73M shares), Sectoral Asset Management Inc (3.72M shares), FMR LLC (3.32M shares), and BlackRock Institutional Trust Company, N.A. (2.91M shares).
This table shows the top 130 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.